DGAP-News: MAB Discovery GmbH: Synthon and MAB Discovery

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

May 6, 2014 at 4:15 AM

DGAP-News: MAB Discovery GmbH: Synthon and MAB Discovery Sign Multi-Target Antibody Discovery Agreement

DGAP-News: MAB Discovery GmbH / Key word(s): Agreement MAB Discovery GmbH: Synthon and MAB Discovery Sign Multi-Target Antibody Discovery Agreement 06.05.2014 / 10:00 --------------------------------------------------------------------- Synthon and MAB Discovery Sign Multi-Target Antibody Discovery Agreement Nijmegen, Netherlands and Neuried, Germany; May 6, 2014: Synthon Biopharmaceuticals BV and MAB Discovery GmbH today announced the execution of a research and license agreement. Under the terms of the agreement, MAB Discovery will generate antibodies for targets selected by Synthon in support of the company's development of antibody-drug conjugates (ADCs) and alternative antibody-based therapeutics. MAB Discovery will employ its in vivo antibody discovery technology platform, which relies on the natural immune response of rabbits followed by state-of-the-art B-cell cloning techniques. Using a novel high-throughput screening route, MAB Discovery focuses on identifying highly active antibodies with unprecedented epitope coverage, potency and species cross-reactivity which has been successful for intractable targets. This technology eliminates affinity maturation and surrogate development which are very time-consuming and often sacrifice function. Synthon will obtain high quality antibodies in support of their strategy to create a portfolio of best-in-class antibody-based therapeutics, including ADCs. Additional details of the transaction were not disclosed. - ENDS - About Synthon Synthon, with headquarters in Nijmegen, The Netherlands, is an international pharmaceutical company and a leader in the field of generic medicines. The company started its biopharmaceutical franchise in 2007 and is building a promising portfolio of next generation medicines. Synthon is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of auto-immune diseases and oncology. Synthon products are currently approved by regulatory agencies in over 80 countries worldwide and marketed through strategic partnerships and - in dedicated areas - through direct sales. Synthon employs about 1,400 staff worldwide, and in 2013 it recorded a turnover of EUR 215 million. For more information, go to www.synthon.com. About MAB Discovery MAB Discovery was founded in Munich, Germany in October 2010. The team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. Funded by PPD Inc., MAB Discovery follows a collaboration-based business model as a basis for its partnerships. Because of their unique funding situation, MAB Discovery can employ flexible business models to meet the needs of their clients. For more information, go to www.mabdiscovery.com. For more information please contact: Synthon: Fabienne Douven Director Corporate Communications +31 24 372 7700 mailto:fabienne.douven@synthon.com MAB Discovery: Dr Birgit Zech Vice President Business Development +49 89 990 178-0 birgit.zech@mabdiscovery.com For media inquiries: MC Services AG Raimund Gabriel Phone: +49 89 210 228-30 raimund.gabriel@mc-services.eu End of Corporate News --------------------------------------------------------------------- 06.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 266495 06.05.2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jill De Forest Honored: A Journey Through Recruitment

A Force in Recruitment: Jill De Forest There's a name that reverberates through the corridors of executive search and recruitment: Jill De Forest. Recognized by The Inner Circle as the Pinnacle Professional of The Year, De Forest has left a profound mark on the industry with her knack for matching exceptional talent to major brands. Trailblazing through Executive Search...

Outdoor Learning: Sparking Preschool Curiosity Weekly

Rekindling Curiosity in Nature’s Classroom With autumn’s crisp air rolling into Greenville, families have a golden opportunity to take learning beyond the traditional classroom. Archway Academy sees the beauty of this season as a sprawling classroom, one that doesn't confine young minds and bodies. For those of us focused more on dollars and sense, the financial...

Braemar's $358 Million Refinance: A Strategic Shift

Reworking the Debt Load: Braemar's New Move Most days, when a company decides to tinker with its debt, it's like watching paint dry for investors. But with Braemar Hotels & Resorts (NYSE: BHR) announcing a $358 million refinancing package, they're bringing a fresh breath of air to the table. Lemme walk you through why this matters beyond the glossy façade of luxury hotel...

Trimble Revamps SketchUp: Game-Changing Design Innovations

Breaking Down Trimble's Latest Moves in Design Software The design world spins on innovation, and Trimble's pushing the boat out with SketchUp 2027. Unveiled at the swanky Trimble Dimensions User Conference in Las Vegas, this revamp is all about smashing through workflow barriers that have tripped up designers for too long. If you've ever haggled with clunky model...

iHeartMedia Faces Investigation; Shares Plummet 60%

A Sudden Pivot Leaves Shareholders Reeling Nothing like a company blindsiding its investors amid the bustling market chaos. Welcome to the iHeartMedia saga, where promises of profit have turned into a bitter pill for shareholders. On November 9, 2026, the radio giant pulled a fast one by drastically revising its full-year Adjusted EBITDA forecast down to $550...

Straight-Talking Look at Zepp Health's Q3 Preview

Prepping for Zepp Health's Financial Disclosure There's something about earnings season that gets the blood pumping. Maybe it’s the anticipation of numbers that can either make us jump for joy or toss us into a pit of despair. November 22 promises to be an intriguing day for folks with eyes on Zepp Health. They're set to spill the beans on their third-quarter...

Decoding Renters vs. Homeowners Insurance Needs

Breaking Down Policy Differences If you've ever scratched your head over the insurance landscape, join the club. Renters and homeowners insurance each serve a specific role on the financial protection battlefield, and knowing what you're signing up for is downright vital. Oscar Salas from HelloNation lays out the core differences for anyone wise enough to get their heads...

Bell Mare to Elevate Senior Living in DC Suburbs

Bringing Upscale Senior Living to Potomac Nothing like luxury to sweeten the twilight years, huh? The Bell Mare at River Road is gearing up to redefine senior living in Potomac, Maryland, aiming to open its doors in Fall 2028. We're talking 94 swanky units—68 for assisted living and 26 for memory care. And these aren't your grandma's digs. Studio, one-, and two-bedroom...

2026 Shaw Prize: Celebrating Science's Global Impact

Shaw Prize: A Global Stage for Science When it comes to celebrating scientific breakthroughs, the Shaw Prize is the gold standard. On November 10th, 2026, the event unfolded at the iconic Hong Kong Convention and Exhibition Centre, and it was all about honoring those pushing the envelope in science. It’s year 23 for the Shaw Prize, and this ceremony didn’t just hand...

Julian Sawyer Strengthens Wirex Board with Expertise

Ah, the world of digital payments – it's like the wild west out there, constantly evolving and full of promise, but with no shortage of challenges. Enter Julian Sawyer, a name that echoes in the hallowed halls of fintech. And guess what? He's bringing his chops to the Wirex Limited board as an Independent Non-Executive Director. If you're in the market game, better keep...